Byakika-Kibwika, PaulineLamorde, MohammedOkaba-Kayom, VioletMayanja-Kizza, HarrietKatabira, EllyHanpithakpong, WaruneePakker, NadineDorlo, Thomas P. C.Tarning, JoelLindegardh, NiklasVries, Peter J. deBack, DavidKhoo, SayeMerry, Concepta2022-01-142022-01-142012Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., ... & Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. Journal of antimicrobial chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr59610.1093/jac/dkr596https://nru.uncst.go.ug/xmlui/handle/123456789/1274Treatment of HIV/malaria-coinfected patients with antiretroviral therapy (ART) and artemisininbased combination therapy has potential for drug interactions. We investigated the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine after administration of a single dose of 80/480 mg of artemether/ lumefantrine to HIV-infected adults, taken with and without lopinavir/ritonavir. Methods: A two-arm parallel study of 13 HIV-infected ART-naive adults and 16 HIV-infected adults stable on 400/100 mg of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (ClinicalTrials.gov, NCT 00619944). Each participant received a single dose of 80/480 mg of artemether/lumefantrine under continuous cardiac function monitoring. Plasma concentrations of artemether, dihydroartemisinin and lumefantrine were measured.enAntiretroviralsAntimalarialsDrug interactionsArticle